- Home
- IONS vs PFSI Comparison
IONS vs PFSI Comparison
Compare IONS & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- PFSI
- Stock Information
- Founded
- IONS 1989
- PFSI 2008
- Country
- IONS United States
- PFSI United States
- Employees
- IONS N/A
- PFSI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- PFSI Finance: Consumer Services
- Sector
- IONS Health Care
- PFSI Finance
- Exchange
- IONS Nasdaq
- PFSI Nasdaq
- Market Cap
- IONS 6.0B
- PFSI 5.4B
- IPO Year
- IONS 1991
- PFSI 2013
- Fundamental
- Price
- IONS $36.91
- PFSI $105.52
- Analyst Decision
- IONS Buy
- PFSI Buy
- Analyst Count
- IONS 18
- PFSI 6
- Target Price
- IONS $62.00
- PFSI $121.33
- AVG Volume (30 Days)
- IONS 1.5M
- PFSI 207.4K
- Earning Date
- IONS 11-06-2024
- PFSI 01-30-2025
- Dividend Yield
- IONS N/A
- PFSI 1.16%
- EPS Growth
- IONS N/A
- PFSI N/A
- EPS
- IONS N/A
- PFSI 3.20
- Revenue
- IONS $803,067,000.00
- PFSI $2,777,781,000.00
- Revenue This Year
- IONS N/A
- PFSI N/A
- Revenue Next Year
- IONS $19.61
- PFSI $39.36
- P/E Ratio
- IONS N/A
- PFSI $32.87
- Revenue Growth
- IONS 30.57
- PFSI 83.37
- 52 Week Low
- IONS $33.33
- PFSI $81.93
- 52 Week High
- IONS $54.44
- PFSI $119.13
- Technical
- Relative Strength Index (RSI)
- IONS 52.98
- PFSI 48.40
- Support Level
- IONS $36.39
- PFSI $103.42
- Resistance Level
- IONS $38.90
- PFSI $106.30
- Average True Range (ATR)
- IONS 1.33
- PFSI 1.90
- MACD
- IONS 0.23
- PFSI -0.21
- Stochastic Oscillator
- IONS 51.63
- PFSI 27.93
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a United States-based financial services company primarily engaged in mortgage lending. The company operates through three segments: production, servicing, and investment management. The company's production and servicing segment together form the mortgage banking business that includes mortgage loan origination, acquisition, and sale activities; while the investment management segment includes investment manager's activities, such as performing diligence, and managing acquired assets. The company generates the majority of revenue from its mortgage banking business.